awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q43921722-054DCF70-A004-466C-AE8A-A6C9D910E23C
Q43921722-054DCF70-A004-466C-AE8A-A6C9D910E23C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43921722-054DCF70-A004-466C-AE8A-A6C9D910E23C
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
P2860
Q43921722-054DCF70-A004-466C-AE8A-A6C9D910E23C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43921722-054DCF70-A004-466C-AE8A-A6C9D910E23C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
210fde8f8d7ce5909cec5cb43db74a2c7b41b70b
P2860
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.